Liminatus Pharma Inc（LIMN）财务数据LIMNLiminatus Pharma Inc

In the context of the broader market, LIMN competes directly with industry leaders such as BGMS and NIKI. With a market capitalization of $4.97M, it holds a significant position in the sector. When comparing efficiency, LIMN's gross margin of N/A stands against BGMS's 23.51% and NIKI's N/A. Such benchmarking helps identify whether Liminatus Pharma Inc is trading at a premium or discount relative to its financial performance.

Liminatus Pharma has shown a troubling financial performance with consistent net losses, including a net income of -8168927.00 USD in Q4 2025 and -1407259.00 USD in Q2 2026. The current ratio has improved to 1.12 in Q2 2026, but the overall financial health remains concerning with a total equity of 300612.00 USD.